• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Febuxostat not effective at delaying progression of carotid atherosclerosis in asymptomatic hyperuricemia

byJack LennonandRavi Shah, MD MBA
May 14, 2020
in Cardiology, Chronic Disease, Nephrology, Neurology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Uric acid-lowering therapy not associated with improved kidney function

Carotid artery stenting and carotid endarterectomy show similar efficacy for stroke prevention in high-risk carotid artery stenosis

Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to allopurinol

1. While there was no placebo control group, treatment with febuxostat for 24 months did not slow carotid atherosclerosis progression in Japanese individuals with asymptomatic hyperuricemia.

 Evidence Rating Level: 2 (Good)

Allopurinol, a purine analogue xanthine oxidase (XO) inhibitor, is a conventional pharmacological intervention for reducing serum uric acid (SUA) levels, which increases risk of cardiovascular disease. Febuxostat, a novel non-purine selective inhibitor of XO, has been found to have greater efficacy in lowering urate and a higher potency for XO inhibition. However, little is known regarding febuxostat and its role in atherosclerosis. This prospective, randomized, open-label, blinded-endpoint clinical trial occurring at 48 sites in Japan between May 2014 and August 2018 sought to examine the relationship between febuxostat and atherosclerosis through measuring carotid intima-media thickness (IMT) progression in patients with asymptomatic hyperuricemia. A total of 483 adult participants (mean [SD] age = 69.1 [10.4] years, 19.7% female) with both maximum IMT of common carotid artery (CCA; ≥ 1.1 mm) and asymptomatic hyperuricemia (SUA ≥ 7.0 mg/dL) were allocated to either dose-titrated febuxostat (n = 239; 10 to 60 mg daily) or a non-pharmacological lifestyle modification for hyperuricemia (n = 244; e.g., diet, exercise changes) based on an intention-to-treat principle. Primary endpoint was change in mean IMT of the CCA from baseline to 24 months, with age, gender, history of type II diabetes, baseline SUA and IMT of the CCA as covariates. No significant differences between groups regarding CCA-IMT were found at baseline (p = 0.65). At 24 months, between group differences were not significant (mean difference -0.016 mm, 95% CI -0.051 to 0.019 mm, p = 0.37). Febuxostat did not demonstrate significant effects on the primary endpoint compared to the control group, nor did it have effects on other carotid ultrasonographic parameters. Regarding mean SUA values at 24 months, the febuxostat group was significantly lower than the control group (mean difference -2.62, 95% CI -2.86 to -2.38, p<0.001). While this study did not include a placebo control group, findings still suggest that 24 months of febuxostat treatment does not slow carotid atherosclerosis progression in Japanese individuals with asymptomatic hyperuricemia.

Click to read the study in PLOS Medicine

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: carotid atherosclerosisfebuxostathyperuricemiauric acid
Previous Post

Mood homeostasis associated with mean mood and depression

Next Post

#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Uric acid-lowering therapy not associated with improved kidney function

June 13, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Carotid artery stenting and carotid endarterectomy show similar efficacy for stroke prevention in high-risk carotid artery stenosis

September 28, 2021
Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout
Cardiology

Febuxostat is not associated with worse cardiovascular safety outcomes or all-cause mortality compared to allopurinol

December 15, 2020
High incidence of foreskin morbidity in uncircumcised males
Chronic Disease

Carotid endarterectomy vs initial medical therapy in asymptomatic carotid stenosis

June 11, 2020
Next Post
#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Factors influencing detectable SARS-CoV-2 viral load

Nivolumab may be effective in platinum-resistant ovarian cancer

Degarelix may be a treatment option for pedophilic disorder

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Methamphetamine use associated with cardiovascular disease in hospitalized patients
  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.